MEETING ABSTRACT





Possibility of $\gamma\delta$ T cell immunotherapy for HTLV-1-infected individuals

Tomoo Sato¹, Masato Muto², Natsumi Araya¹, Ryuji Maekawa², Noboru Suzuki¹, Atae Utsunomiya³, Ken-ichiro Seino⁴, Yoshihisa Yamano^{1*}

From 15th International Conference on Human Retroviruses: HTLV and Related Viruses Leuven and Gembloux, Belgium. 5-8 June 2011

 $\gamma\delta$ T cells, a small subset of T lymphocytes, are involved in innate immunity. It has been demonstrated that $\gamma\delta$ T cells have cytotoxic activities against cells infected with a variety of viruses. However, there is little evidence suggesting a cytotoxic activity of $\gamma\delta$ T cells against HTLV-1-infected cells. Therefore, we investigated whether $\gamma\delta$ T cells play a protective role in the defense against HTLV-1.

Using PBMCs from asymptomatic carriers (ACs) and HAM/TSP patients, we assayed the frequency of CD3 $+V\gamma9+(\gamma\delta T)$ cells and the correlation between its frequency and the HTLV-1 load. The frequency of $\gamma\delta$ T cells was significantly decreased in HAM/TSP patients compared with that in ACs. The frequency of $\gamma\delta$ T cells was inversely correlated with the proviral load. These results suggest that $\gamma\delta$ T cells have a protective effect on HTLV-1-infected individuals. Next, CD3+Vy9+ cells and CD3+Vy9- cells were separated from PBMCs of HTLV-1-infected persons by FACS and the proviral load of each population was quantified by real-time PCR. The proviral load in $\gamma\delta$ T cells was markedly lower than that in CD3+ lacking $\gamma\delta$ T cells. Furthermore, we cultured PBMCs from HTLV-1-infected individuals in the presence of IL-2 and zoledronate. In some cases, the majority of cells contained in these cultures became $\gamma\delta$ T cells and the proviral load was markedly decreased. The cultured PBMCs showed strong cytotoxic activities against a HTLV-1-infected cell line as well as an ATL cell line. These results raise the possibility of $\gamma\delta$ T cell immunotherapy in HTLV-1-infected individuals.

Full list of author information is available at the end of the article



Author details

¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan. ²Medinet Medical Institute, MEDINET Co. Ltd., Tokyo, Japan. ³Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. ⁴Institute for Genetic Medicine Research Section of Pathophysiology, Hokkaido University, Hokkaido, Japan.

Published: 6 June 2011

doi:10.1186/1742-4690-8-S1-A109

Cite this article as: Sato *et al.*: Possibility of $\gamma\delta$ T cell immunotherapy for HTLV-1-infected individuals. *Retrovirology* 2011 8(Suppl 1):A109.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

) BioMed Central

Submit your manuscript at www.biomedcentral.com/submit

© 2011 Sato et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

^{*} Correspondence: yyamano@marianna-u.ac.jp

¹Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan